Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer

NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE

Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors: A Meta-analysis

Therapy With 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors

Quality of life in patients with midgut NET following peptide receptor radionuclide therapy

Caring for Patients Receiving 177Lu-DOTATATE, Lutathera®: A Treatment of Hope for Patients With Gastroenteropancreatic Neuroendocrine Tumors

A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radioisotope Therapy for Patients With Neuroendocrine Tumors

Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors

Impact of Liver Tumor Burden on Therapeutic Effect of 177Lu-DOTATATE Treatment in NETTER-1